---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-022333"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:29.426517+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q2 net sales up 27.8% to $140.3M; net loss improves to $8.0M; updates FY22 guidance

## Summary
- Net sales of $140.3M (+27.8% YoY); organic growth of 8.1%. Surgical Solutions vertical up 77.2%.
- GAAP net loss of ($8.0M) vs ($10.8M) in Q2 2021; diluted loss per share ($0.11) vs ($0.10).
- Adjusted EBITDA of $22.9M vs $19.9M YoY; Non-GAAP EPS $0.10 vs $0.11.
- FY22 guidance narrowed: net sales $547.5-562.5M (mid-point unchanged); adjusted EBITDA $94-104M.
- Discontinued MOTYS development; completed CartiHeal acquisition on July 12, 2022.

## SEC filing metadata
- accession: 0001628280-22-022333
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022022333/0001628280-22-022333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022022333/bvs-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-022333
- JSON: https://secwatch.observer/filing/0001628280-22-022333.json
- Plain text: https://secwatch.observer/filing/0001628280-22-022333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.